Plain-English translation of NCT06793033 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing the NEURESCUE device, a balloon catheter that temporarily blocks blood flow in the aorta (the main artery leaving the heart) during cardiac arrest. Researchers want to see if using this device alongside standard emergency heart attack treatment can help more patients survive and recover better. Half of the participants will receive standard treatment alone, and the other half will receive standard treatment plus the NEURESCUE device.
When the heart stops beating, every second counts—standard emergency treatment saves some lives, but many patients still don't survive. This trial exists to find out whether this new device can redirect blood flow to protect the brain and heart during cardiac arrest, potentially improving survival rates and patient outcomes.
You likely qualify if…
You likely don't qualify if…
If you qualify and agree to participate, you will be randomly assigned to receive either standard emergency heart attack treatment alone, or standard treatment combined with the NEURESCUE device. Your heart rhythm and recovery will be carefully monitored during and after treatment. You'll have 4 follow-up visits over 90 days, with the final visit occurring 90 days after your cardiac arrest to check on your overall recovery.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
Germany